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Abstract
Cofactors are intimately involved in steroid-regulated gene expression. Two critical questions are (1) the steps at which
cofactors exert their biological activities and (2) the nature of that activity. Here we show that a new mathematical theory of
steroid hormone action can be used to deduce the kinetic properties and reaction sequence position for the functioning of
any two cofactors relative to a concentration limiting step (CLS) and to each other. The predictions of the theory, which can
be applied using graphical methods similar to those of enzyme kinetics, are validated by obtaining internally consistent data
for pair-wise analyses of three cofactors (TIF2, sSMRT, and NCoR) in U2OS cells. The analysis of TIF2 and sSMRT actions on
GR-induction of an endogenous gene gave results identical to those with an exogenous reporter. Thus new tools to
determine previously unobtainable information about the nature and position of cofactor action in any process displaying
first-order Hill plot kinetics are now available.
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Introduction
Ligand-regulated gene induction is a productive experimental
system for examining the mechanisms of gene expression. Steroid-
regulated gene induction is an extensively studied paradigm with
numerous well-defined events. The initially formed, intracellular
receptor-steroid complex binds to specific enhancer-like DNA
elements (called hormone response elements, or HREs) to
eventually modify the rates of transcription of target genes. Other
steps include recruitment of chromatin remodeling factors and
cofactors that increase or decrease the rates of transcription [1–3].
One approach to defining steroid receptor actions at the
molecular level has been to pair ChIP assays with genome-wide
sequencing to identify all DNA binding sites of selected cofactors
in the cellular genome [4]. Nonetheless, limitations to this
approach remain. Not all factor binding sites are functionally
active [5,6]. The HREs may not regulate the closest gene [7],
which is the default assignment. Methods to identify new cofactors
are not generally available and the kinetic mechanism of most
factors and cofactors is unknown. Because virtually all possible
responses to steroid hormones have been observed with endoge-
nous genes [8], no general mode of action exists. Finally, one can
determine the temporal ordering of cofactor binding to DNA but
no method exists to elucidate the temporal ordering of biological
function. Cofactor binding to DNA is not equivalent to cofactor
action. For example, paused RNA polymerase II is often present
50 bp downstream of the start of transcription but is not engaged
in transcription [9–11]. Thus there is an unmet need for methods
that can discern the precise nature (e.g., activator, non-competitive
inhibitor) and temporal order of cofactor function.
Here we describe a method that establishes the functional
mechanism and order of action of any active factor/cofactor
relative to what we call a ‘‘concentration limiting step’’ (CLS). The
method is derived from a recently developed theory of gene
expression that is applicable to receptor-mediated transcriptional
events that display a first-order Hill plot dose-response curve
(FHDC) [12] for the gene product in experiments that reach
equilibrium or steady state. The CLS is analogous to the rate-
limiting step for a closed system and provides a reference point for
the actions of all other cofactors. The method is based on
analyzing graphs constructed from the maximal activity (Amax) and
potency (EC50) of the FHDC. Importantly, two cofactors can be
assayed simultaneously and the graphical method determines the
functional nature and order of both cofactors relative to each other
and the CLS. This approach is amenable to screening cofactors
because prior knowledge about their action is not required.
Results
Application of the theory to analyzing the actions of
cofactors
The graphical method is derived from our steroid-mediated
gene induction theory, which can generate a parametric model
(i.e. formula) for the dose-response curve of the final protein
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an arbitrary number of cofactors [12] (see Text S1 for the
derivation). The theory considers a sequence of reaction steps,
each with the form
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where Yi is the reaction product of step i, Xi is an activating
cofactor or activator, and Ii is an inhibiting cofactor or inhibitor.
The labels on the reactions represent association constants for
reversible reactions and reaction rates for nonreversible reactions.
As in enzyme kinetics, we denote the case of a~0 to be competitive
inhibition, c~0 to be uncompetitive inhibition, a~c to be
noncompetitive inhibition, and a and c both nonzero to be mixed
inhibition. The case of b~0 is called linear inhibition, and bw0 is
called partial inhibition. In general, computing the dose-response
curve for such a reaction sequence would be analytically
intractable. However, imposing the experimentally observed
constraint that the dose-response curve has a Hill-coefficient of
one yields a closed-form expression for the dose-response curve in
terms of the parameters of all the reactions.
The theory identifies a CLS, which is a step in the reaction
sequence in which products of the reactions following it (post-CLS
steps) are so small that the amounts of cofactor bound are
negligible compared to their free concentrations [12]. A cofactor
can act before, at, or after the CLS. It can be an activator or one of
the four types of inhibitor and each inhibitor can be linear or
partial. Although there are eight possible types of inhibitor (e.g.
partial uncompetitive, linear noncompetitive, etc.), some combi-
nations are not possible (e.g. a competitor cannot be partial).
Inhibitors refer to their action in their particular reaction and not
to the final product. For example, a partial inhibitor can give a
higher response if it diverts the output to a higher yielding
pathway. In fact, the action of a partial uncompetitive inhibitor is
similar to an activator acting in a post-CLS step. For two cofactors,
there are at most 285 possible cases accounting for where they act
with respect to each other and the CLS, with each cofactor being
either an activator or one of eight possible types of inhibitors. It
should be noted that not all types of inhibitors are physically viable
or can act in all locations. For example, among all types of
inhibition, only competitive inhibition occurs after the CLS and
partial competitive inhibition cannot exist. Each viable case is
represented by an explicit parametric model that can be compared
to the data (see Text S1).
We previously deduced that Ubc9 was an activator acting after
the CLS by fitting parametric models directly to the data [12].
However, in that case there were only three models to test. For the
more general case with multiple cofactors, directly fitting models
to the data is unwieldy. However, the models have very different
qualitative behaviors for different types of cofactors and their
positions of action. In particular, the EC50 (steroid concentration
required for half-maximal activity) and Amax (maximal activity)
behave very differently with changing cofactor concentration. The
graphical method exploits these differences to predict mechanism
and position from the properties of graphs of functions of EC50 and
Amax versus cofactor concentration. Hence, the cofactor mecha-
nism and position of action is inferred from the qualitative
behavior of how the dose-response curve changes and does not
require making direct estimates of the parameter values.
Graphical analysis of single cofactor actions
We applied our method to two well-known cofactors for
glucocorticoid receptor (GR, also called NR3C1) transactivation:
the coactivator TIF2 and the corepressor SMRT [13,14]. To
obtain easily quantifiable data for graphical analysis, the induction
of a synthetic reporter gene (GREtkLUC) by GRs is followed in
transiently transfected cells with different cofactor concentrations
and triplicate sub-saturating concentrations of the glucocorticoid
dexamethasone (Dex). The Amax and EC50 are abstracted from fits
of the data points to a first order Hill function (Fig. 1A). Graphs of
1/EC50 vs. concentration and Amax/EC50 are then plotted.
Figure 1B shows the plot of 1/EC50 vs. transfected TIF2
plasmid (after correction for frequent non-linear expression of
plasmid-encoded protein [see Text S1 and Fig. S1]) for an
experiment with four TIF2 concentrations. The curve is seen to be
increasing and according to the theory, the only possible
parametric models are a straight line with a positive slope or a
nonlinear rational function. The data are seen to be consistent
with being linear. Although it is true that a nonlinear function is
possible it is far less parsimonious. We thus first assume that the
curves are linear and check for logical consistency with the other
predictions (see Text S1 for full algorithm to determine shape of
the curves). If linearity fails to give a logically consistent prediction
then we can test the hypothesis that the curves are nonlinear.
According to Table 1, linear with positive slope is characteristic of
TIF2 acting in one of three manners. (Note: all below graphs are
for corrected non-linear protein expression.) The interpretation of
the linear plot of Amax/EC50 vs. TIF2 (Fig. 1C) depends upon the
y-axis intercept when the total TIF2 (endogenous plus added)
equals zero. The relative amount of endogenous TIF2 was
determined by Western blotting to be equivalent to 0.97 ng of
transfected TIF2 plasmid (not shown). Experiments with fluores-
cent-tagged proteins indicated that ,50% of the cells are
transfected. Thus, endogenous TIF2 in transfected cells equals
about 0.49 ng TIF2 plasmid. The average x-axis intercept from 4
experiments like Fig. 1C is 25.663.6 (S.D.) ng of TIF2 plasmid.
Therefore the Amax/EC50 plots intersect the x-axis at less than
‘‘true zero’’ (i.e., less than no endogenous TIF2). Consequently the
y-axis intercept is .0. From Table 1A, we now conclude that
TIF2 is an activator after the CLS or the mathematically
indistinguishable case of a partial uncompetitive inhibitor before
the CLS.
The originally described form of SMRT, sSMRT [15], lacks
about 1000 amino-terminal residues [16]. Both sSMRT and full
length SMRTs are corepressors of steroid receptor action.
Graphical analysis of sSMRT as above with a constant, low
amount of exogenous TIF2 (to increase the starting signal), yields a
decreasing curve for 1/EC50 vs. sSMRT (Fig. 1D). The only
allowable form of this curve by the theory is a decreasing nonlinear
first-order decay plot. The plot of Amax/EC50 is also first-order
decay (Fig. 1E). The important characteristic of decaying curves is
whether they decay to zero or a positive value asymptotically. This
can be determined graphically by plotting the reciprocal function
(EC50/Amax) and seeing if it is linear, which is confirmed in Fig. 1F.
The only interpretation in Table 1 compatible with Figs. 1D–F is
that sSMRT is a competitive inhibitor before or at the CLS.
Graphical analysis of dual cofactor actions (TIF2 vs.
sSMRT)
Our method can simultaneously analyze two cofactors and
determine the site of each cofactor’s action relative to the CLS,
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EC50 and Amax/EC50 for each cofactor), plus information on
plasmid expression efficiency, are needed for maximal informa-
tion, often with quantitation of endogenous cofactor. More than
one classification of each plot may appear possible. However, by
eliminating incompatible mechanistic consequences, one almost
always reaches a single, internally logically consistent mechanistic
description. Favorable conditions are with two cofactors of
opposite activities, thereby yielding the greatest changes. As
TIF2 and sSMRT fit these criteria, we analyzed their actions using
four concentrations of each cofactor in all combinations, plus a
control of no added cofactors.
Figure 2A shows that plots of Amax/EC50 vs. TIF2 plasmid for
increasing sSMRT consists of lines with progressively lower
positive slopes. Western blots indicated that endogenous TIF2 in
these experiments equaled 4.1 ng of TIF2 plasmid (data not
shown). Entries 23,25, 28, and 29 of Table S1 are consistent with
these graphs. Deciding between these entries for Fig. 2A depends
upon the x- and y-axis coordinates of the intersection point of the
lines. The x-axis value was determined, from what we call an ‘‘a
vs. b plot’’ (Fig. 2B; see Methods), to be more negative
(Ave.=28.661.4, S.D., n=4) than the endogenous TIF2
(24.1), while the y-axis value was 2.362.2. This restricts the
possible graphical interpretations to entries 25 and 29. Coupled
Figure 1. Analysis of actions of excess TIF2 or sSMRT. (A) Determination of Amax and EC50 by exact fit of gene induction response. Luciferase
activity in transiently transfected U2OS cells (100 ng GREtkLUC reporter, 0.5 ng of GR, and the indicated amounts of TIF2 plasmid) is plotted against
Dex concentration. The Amax and EC50 were determined from the best-fit curve to a first order Hill plot as described in Materials and Methods. Plots of
1/EC50 (B) and Amax/EC50 (C) vs. TIF2, corrected for non-linear protein expression as described in the Text S1. The dashed line is the extrapolation of
the linear best-fit of the data. The dotted line equals the position of the y-axis at ‘‘true zero’’ of no TIF2 in cells. Plots of 1/EC50 (D) and Amax/EC50 (E) vs.
sSMRT, corrected for non-linear protein expression. The Amax and EC50 for Dex induction of Luciferase activity in transiently transfected U2OS cells
(100 ng GREtkLUC reporter, 0.5 ng of GR, 3 ng of TIF2 and the indicated amounts of sSMRT plasmid) was determined as in A. (F) Amax/EC50 vs.
corrected sSMRT approaches zero at infinite sSMRT. A linear plot of Amax/EC50 vs. corrected sSMRT is diagnostic of an asymptote value equal to zero
at infinite sSMRT. A positive asymptote value would give a non-linear, downward curving plot that can be linearized by subtracting the estimated
asymptote from each of the values for Amax/EC50 in panel E and then plotting the reciprocal (1/[(Amax/EC50) – asymptote]). The combined results from
this one representative experiment were seen in three other independent experiments.
doi:10.1371/journal.pone.0030225.g001
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(Fig. 2C; x-axis intercept=28.963.0)), the possible behavior of
TIF2 and sSMRT reduces to: TIF2 is an activator acting after the
CLS, sSMRT is a competitive inhibitor acting at the CLS and
before TIF2. The other plots of 1/EC50 vs. sSMRT (Fig. 2D),
Amax/EC50 vs. sSMRT (Fig. 2E), and EC50/Amax vs. sSMRT
(Fig. 2F) can each be described by entries 18, 32, and 37
respectively with the same unique mechanistic interpretation as
above.
Graphical analysis of TIF2 and NCoR competition
NCoR is another well-documented corepressor that is thought
to act like sSMRT [13,14]. We investigated the actions of NCoR
competing with TIF2 under the conditions of Fig. 2. Western blots
were used to correct for non-linear expression and to determine
relative endogenous TIF2 (4.1 ng TIF2 plasmid) and NCoR
(8.3 ng NCoR plasmid) levels. Given these values, only entries 26
or 27 can describe the graph of Amax/EC50 vs. NCoR (Fig. 3A),
with calculated x- and y-intersection points of 230.0626.7 and
1.261.0 (S.D., n=6) respectively. Thus NCoR is an activator
acting after the CLS and TIF2 is an activator acting after the CLS.
Each of the other graphs has more than one potential classification
due to insufficient precision in the graphical intersection points:
Amax/EC50 vs. TIF2 (Fig. 3B; entries 24 and 27), 1/EC50 vs.
NCoR (Fig. 3C; 6, 7, and 11), and 1/EC50 vs. TIF2 (Fig. 3D;
entries 5–7 and 11). However, most graphical options are
incompatible with both factors being activators after the CLS
and can be eliminated to yield: NCoR is an activator acting after
the CLS, TIF2 is an activator after the CLS, and TIF2 and NCoR
do not act at the same step. While these data are not yet able to
determine whether TIF2 is an activator after or before NCoR, the
conclusion that TIF2 is an activator after the CLS is identical to
the above results with TIF2 vs. sSMRT.
Graphical analysis of sSMRT and NCoR competition
To confirm the above different actions of sSMRT and NCoR,
we directly competed the activities of both cofactors under
conditions of Fig. 2. Here the key graphs again involve Amax/
EC50. For NCoR (Fig. 4A), the calculated x-axis intersection of
274631 is clearly less than the 28.3 of endogenous NCoR while
the y-axis intersection is 20.0460.4 (S.D., n=3). These properties
are uniquely defined by entry 25. Deciding whether Amax/EC50
vs. sSMRT (Fig. 4B) is described by entry 32 or 33 is resolved by
the linear plots of EC50/Amax (Fig. 4C). This characteristic of
entry 37 is obtained only when nonlinear decreasing Amax/EC50
plots approach zero with infinite F2. At this point, we can
conclude that: NCoR is an activator after the CLS, sSMRT is a
competitive inhibitor before or at the CLS, and NCoR acts after
sSMRT. The 1/EC50 graphs with either factor are consistent with
several interpretations (entries 8–10 and 12 for NCoR and 18 and
19 for sSMRT; Fig. S2), one of which is, for each factor, the same
as that derived from the other graphs. It is not possible with these
data, though, to determine whether sSMRT acts before or at the
CLS.
Graphical analysis of TIF2 and sSMRT competition for
induction of an endogenous gene
The relevance of the above competition of TIF2 and sSMRT,
and the applicability of the graphical analysis to normal cellular
biology, was next examined in the context of the GR-inducible
IGFBP1 gene in U2OS cells [17–19]. qRT-PCR quantitation of
IGFBP1 mRNA induction employed SyberGreen, which gives
relative total activities. Therefore, the Amax in these experiments is
actually the closely related fold-induction above basal level. 1/
EC50 vs. TIF2 graphs (Fig. 5A) are exclusively described by entry
9 because the ‘‘a vs. b plots’’ give an x-axis intersection point
(23.560.6, S.D., n=4) that is much more negative than the
endogenous TIF2 in these experiments of 20.49. The non-linear
Amax/EC50 (Fig. 5B), with the linear EC50/Amax (Fig. 5C),
graphs vs. sSMRT implicate entries 32 and 37 respectively, which
define the factors as: TIF2 is an activator after the CLS, sSMRT is
a competitive inhibitor at the CLS, and TIF2 acts after sSMRT.
The predictions from the other graphs (Amax/EC50 vs. TIF2 and
1/EC50 vs sSMRT; Fig. S3) are entirely consistent with this
interpretation. Gratifyingly, this conclusion is the same as seen
above for these factors with an exogenous reporter gene.
Discussion
This report describes how a new mathematical theory of
steroid-induced gene transcription [12] gives previously unobtain-
able mechanistic information about GR- (NR3C1-) regulated gene
induction. This information could be obtained from direct curve
fitting of predictions from our theory but it would be extremely
computationally intensive. Instead, we carefully examined the
underlying equations of the theory. This analysis unexpectedly
revealed that plots used in enzyme kinetics can be adapted to
analyze the role of cofactors in GR-mediated gene transactivation.
Table 1. Algorithms for single factor plots for factor F.
Plot parameters Plot properties Mechanistic conclusions
1/EC50 vs. F linear with zero slope (i.e. does not change with F) 1) F=A at CLS or 2) F=PN before CLS
linear with positive slope 1) F=A not at CLS; or 2) F=U before or at CLS, or 3) F=PU
before CLS
nonlinear decreasing curve (concave-up) 1) F=C, 2) F=M before or at CLS
nonlinear increasing curve (concave-down) 1) F=LM or PM, before CLS; or 2) F=M at CLS
Amax/EC50 vs. F linear; y-axis intercept=0 1) F=A before or at CLS
linear; y-axis intercept .0 1) F=A after CLS; or 2) F=PU before or at CLS
nonlinear decreasing curve that approaches zero for large F F=C before or at CLS
nonlinear decreasing curve that approaches positive value for large F 1) F=PM or PN, before or at CLS; or 2) F=C after CLS
nonlinear increasing curve 1) F=PM or PN, before or at CLS
EC50/Amax vs. F linear with positive slope 1) F=C before or at CLS
doi:10.1371/journal.pone.0030225.t001
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cofactor function and also the location in the reaction scheme
where the cofactor is acting relative to a CLS. A major advantage
of these graphical methods is that they are readily employed
without the needs of elaborate and extensive mathematical
calculations. Our method works with a single added cofactor but
is more informative when two cofactors are examined together, in
which case the nature and location of action of both cofactors can
be determined simultaneously. Even if a precise mechanistic
interpretation is not possible, differences in the graphical analyses
can reveal mechanistic non-equivalence of two cofactors that
otherwise may be thought to share a common mode of action.
Several approaches were taken to validate our graphical analysis
using GR-regulated gene induction as the model system. The p160
family member, TIF2, is a well-documented coactivator of steroid
receptors [13,20,21]. In three different systems, TIF2 was always a
activator acting after the CLS. Likewise, the corepressor sSMRT
[13,20,21] was always found to be a competitive inhibitor, acting
at the CLS in two systems and at or before the CLS in the third.
To our knowledge, this is the first identification regarding either
the kinetics of mechanism, or placement of action, of TIF2 or
sSMRT.
A major test of our graphical methods came upon examining
the actions of three cofactors (TIF2, sSMRT, and NCoR) in all
possible pair-wise combinations. The mechanism and site of action
of each cofactor was the same in competition assays with both of
the other two cofactors. This internal logical consistency of
cofactor mechanism and site of action strongly validates our new
method. It also suggests that there is just one CLS, which does not
change with assay conditions. This is important in ascertaining
whether the CLS is invariant and a common marker step when
comparing the actions of different cofactors.
Figure 2. Analysis of combined actions of TIF2 and sSMRT. (A) Graph of Amax/EC50 vs. TIF2. The results of one representative experiment
(n=4), conducted as in Fig. 1, are shown for the indicated amounts of transfected TIF2 plasmid, corrected for non-linear protein expression. (B).
Determination of intersection coordinates. The coefficients ‘‘a’’ and ‘‘b’’ of the linear plots in A, described by y=a+bx, are graphed. The negative value
of the slope, and y-axis intercept, in this graph give the x- and y-axis the values respectively for intersection point of the lines in A, as described in the
text and Text S1. Data for one representative graph each (n=4) of 1/EC50 vs. TIF2 (C) or sSMRT (D), of Amax/EC50 vs. sSMRT (E) and of EC50/Amax vs.
sSMRT (F) were acquired as in A and plotted against the indicated amounts of transfected plasmids, each of which have been corrected for non-linear
protein expression.
doi:10.1371/journal.pone.0030225.g002
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works with endogenous genes. The fact that the mechanisms of
TIF2 and sSMRT in IGFBP1 induction involve identical sites of
action as seen with the transiently transfected GREtkLUC
reporter is further support for both the utility of our method and
for the invariance of the CLS. Also, it has long been assumed
that most steps of GR-regulated gene induction are the same for
exogenous and endogenous genes. We recently demonstrated
that the modulatory activity of TIF2 is very similar with both
types of reporters [22]. The present data suggest that the mode
and site of TIF2 action may also be the same with both classes of
reporters.
The different manners of NCoR and sSMRT action was
unexpected. NCoR and sSMRT are generally thought to act as
corepressors by binding to nearly the same site as coactivators,
thereby excluding coactivator binding [23,24]. Not only does our
graphical analysis indicate different mechanisms of action at
different steps for NCoR and sSMRT but also NCoR, being
kinetically defined as an activator, could be called a coactivator
because it increases the Amax in U2OS cells. However, this
property of NCoR is cell-dependent, with NCoR decreasing the
Amax from GREtkLUC in Cos-7 cells and increasing the Amax in
293 cells (Fig. 6). Such cell-selective differences are not unique
and have been seen not only for sSMRT with estrogen receptors
in HeLa cells [25], and GR in CV-1 vs. 1407.2 cells and
progesterone receptors in 1470.2 cells [26], but also with ZAC1b
[27] and CIA with estrogen receptors [28], and with SRAP
activation of androgen receptors and repression of VP16
transactivation [29]. In a recent report, 19 of 25 cofactors
examined have dual activity and can increase and decrease the
activity of agonist steroids with the androgen receptor in a gene-
dependent manner [30]. It will be interesting to use our graphical
analysis to determine the precise kinetic properties of the context-
dependent activities of these versatile cofactors.
Figure 3. Analysis of combined actions of TIF2 and NCoR. Graphs of Amax/EC50 vs. NCoR (A) and TIF2 (B) and of 1/EC50 vs. NCoR (C) and TIF2
(D). The results of one representative experiment (n=6), conducted as in Fig. 1, are shown for the indicated amounts of transfected TIF2 and NCoR
plasmids, corrected for non-linear protein expression.
doi:10.1371/journal.pone.0030225.g003
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process not displaying FHDC kinetics of induction or repression
cannot be analyzed. Conversely, our approach is applicable to any
process yielding FHDC kinetics such as hormones in general [31],
G-protein mediated responses [32,33], the developmental-specific
genes of Drosophila embryogenesis [34], and glucocorticoid-
induced apoptosis of thymocytes [35]. While we have yet to
discover a straightforward method to determine the graphical
consequences of every mechanistic combination, the most
common mechanisms listed in Table S1 cover over 74% of the
possible cases. Thus, some graphical patterns may emerge that
have not yet been linked to a specific mechanism. Nonetheless, the
current range of analyzable mechanisms offers a powerful method
for determining two aspects of steroid hormone action for which
no alternative method presently exists: the kinetic actions of
cofactors and the relative ordering of cofactor activity in the
overall pathway. With this last capability, it is now theoretically
possible to construct an ordered sequence based on the biological
function of cofactors, much as in the ordering of pathways by
epistasis analysis, even if the biochemical properties of the
cofactors are not known. As a start, the present experiments in
U2OS cells reveal that TIF2 and NCoR act at different steps after
the CLS and after sSMRT, which acts at the CLS. This type of
information should be useful in identifying downstream steps for
therapeutic intervention, thereby reducing the number of side-
effects that accompany the inhibition of upstream steps in steroid
hormone action.
Materials and Methods
Unless otherwise indicated, all cell growth was at 37uC and all
other operations were performed at r.t.
Figure 4. Analysis of combined actions of NCoR and sSMRT. Graphs of (A) Amax/EC50 vs. NCoR, (B) Amax/EC50 vs. sSMRT, and (C) EC50/Amax vs.
sSMRT. The results of one representative experiment of a total of three independent experiments, conducted as in Fig. 1, are shown for the indicated
amounts of exogenous NCoR and sSMRT plasmids, after correction for non-linear protein expression.
doi:10.1371/journal.pone.0030225.g004
Figure 5. Analysis of combined actions of TIF2 and sSMRT for induction of the endogenous gene, IGFBP1. Plots of (A) 1/EC50 vs. TIF2,
(B) Amax/1006EC50 vs. sSMRT, and (C) EC50/Amax vs. sSMRT. The results of one representative experiment of a total of four independent experiments,
conducted similarly as in Fig. 1, are shown for the indicated amounts of transfected NCoR and sSMRT plasmids, after correction for non-linear protein
expression. The differences are that IGFBP1 mRNA (instead of luciferase) was determined by qRT-PCR and fold-induction is used in place of Amax (see
text).
doi:10.1371/journal.pone.0030225.g005
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Dexamethasone (Dex) was purchased from Sigma (St. Louis,
MO). Dex-21-mesylate (DM) was from Steraloids (Newport, RI).
Anti-TIF2 mouse monoclonal antibody (No. 610984; BD Biosci-
ences, San Jose, CA), anti-b actin monoclonal antibody (Sigma, St.
Louis, MO), and goat anti-mouse horseradish peroxidase (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) are commercially
available. Rabbit anti-NCoR antibody was a gift from Goeffrey
Rosenfeld (UC San Diego, CA).
Plasmids
The GREtkLUC reporter is a synthetic plasmid with a tandem
repeat of the second glucocorticoid response element (GRE) of the
rat tyrosine aminotransferase gene fused upstream of the
thymidine kinase (tk) promoter driving the firefly luciferase
(LUC) gene [36]. Renilla TS is a gift from Nasreldin M. Ibrahim,
Otto Fro ¨hlich, and S. Russ Price (Emory University School of
Medicine), pSG5/TIF2 is from Heinrich Gronemeyer (IGBMC,
Strasbourg, France), pCMX/sSMRT is from Ronald Evans (Salk
Institute, La Jolla, CA), NCoR/Flag is from Geoff Rosenfeld
(University of California-San Diego, San Diego, CA), and rat GR/
pSG5, pSG5/human serum albumin, pCMX/human serum
albumin, and pBSK have been previously described [37–40].
The Renilla null luciferase reporter is from Promega (Madison,
WI).
Cells and Growth Conditions
U2OS human osteosarcoma cells (from ATTC, #HTB-96)
were grown in high glucose DMEM (Invitrogen, Carlsbad, CA)
with 10% fetal bovine serum as previously described for U2OS
cells with stably transfected GR (17). Cells were split at 3- to 4-day
intervals and used in experiments at approximately 60–90%
confluence. For steroid treatments, Dex and DM solutions were
prepared in 100% ethanol and diluted $1:100 into growth
medium. Growth medium for the cells was then replaced with
ethanol- or steroid-medium for the indicated incubation time.
Transient Transfection and Reporter Analysis
U2OS cells (20,000 cells per well) were seeded 24 h before
transfection in 24-well plates. GREtkLUC reporter plasmid
(100 ng/well) and other plasmids (total DNA adjusted to
300 ng/well with pBluescriptII SK+ [Stratagene, Santa Clara,
CA]) were transiently transfected with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. Cells were treated 24 h post-transfection with steroids
for 16–20 h and assayed for luciferase activity using a dual-
luciferase reporter assay (Promega, Madison, WI) on a Centro XS
3
LB 960 luminometer (Berthold Technologies, Oak Ridge, TN).
Luciferase activity was normalized to Renilla TS as an internal
control.
Quantitative Real-Time PCR (qRT-PCR)
U2OS cells (150,000–200,000 cells per well) were seeded 24 h
before transfection in 6-well plates. Plasmids (total DNA=
1500 ng/well) were transiently transfected with Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions in
the same ratios as used for 24-well dishes. Cells were treated 24 h
post-transfection with various concentrations of Dex and DM for
20 h. Total RNA was extracted using TriZol reagent (Invitrogen)
and cDNA was synthesized using SuperScript III, First-Strand
Synthesis Kit (Invitrogen) per manufacturer’s recommendations.
The relative expression level of the corresponding cDNA was
quantified using SyberGreen in an ABI 7900HT real-time PCR
system. The quantification was normalized against b-Actin using
the 2
2DDCT method. For all qRT-PCR reactions, primer
efficiencies were 100% (610%), appropriate no-RT and template
free controls were used, and primer melting curves were assessed
to ensure specificity of the PCR products.
Western Blotting
U2OS cells were transiently transfected with TIF2 expression
plasmid under conditions identical to those above. After 48 h, cells
were lysed using Cytobuster Protein Extraction Reagent (EMD
Chemicals, Gibbstown, NJ) and equal amounts of lysate run on 4–
12% Bis-Tris NuPAGE gels (Invitrogen) per manufacturer’s
instructions. Western blots were prepared, probed with mouse
anti-TIF2 or mouse anti-b actin antibody followed by goat anti-
mouse horseradish peroxidase. Bands were visualized with
enhanced chemiluminescence detection reagents as described by
the manufacturer (GE Healthcare, Piscataway, NJ). The relative
concentration of target proteins was determined by densitometric
analysis of the exposed film.
Data analysis
Statistical significance for Luciferase activity is assessed by the
two-tailed Student’s t test using InStat 2.03 (GraphPad Software,
San Diego, CA). Each average of triplicates is treated as one
value of the n experiments. When the difference between the SDs
of two populations is significantly different, the t test is invalid so
the Mann-Whitney or Alternate Welch t-test is used. A
nonparametric test is used if the distribution of SD values is
non-Gaussian.
The maximum induced activity (Amax) was obtained with
saturating concentrations of agonist steroid, which was the lower
of $100-fold higher than the EC50 or 10 mM. One dose-response
curve yields one value of EC50 via a curve-fitting program
(KaleidaGraph; Synergy Software, Reading, PA) following a first
order Hill plot for increase or decay (R
2 almost always $0.95).
Alternatively, we can determine Amax and EC50 directly by fitting
the curve
Figure 6. Cell-selective activity of NCoR. Cos-7 or 293 cells were
transiently transfected with the same amount of plasmids for
glucocorticoid receptor (0.5 ng), NCoR (90 ng) or equimolar amount
of control plasmid (51.6 ng of human serum albumin in the pCMX
vector), and GREtkLUC reporter and induced with EtOH 61 mM Dex as
described in Materials and Methods. The total Luciferase activity with
1 mM Dex with each treatment was expressed relative to that with no
added NCoR (6 S.D., n=3). P values: *#0.021.
doi:10.1371/journal.pone.0030225.g006
Deducing the Temporal Order of Cofactor Function
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30225y~
Vx
1zWx
where V=Amax/EC50 and W=1/EC50.
Graphical analysis
After obtaining Amax/EC50 and 1/EC50 from the dose response
curve, graphs of Amax/EC50 vs. C and 1/EC50 vs. C, where C is
the concentration of a cofactor, were constructed. In experiments
where two cofactors were assayed, graphs of Amax/EC50 vs. C and
1/EC50 vs. C for each cofactor for varying concentrations of the
other cofactor would be made. Thus, if an experiment used n
concentrations for each cofactor, then there would be a total of
four to six graphs, each with n separate curves, that are analyzed as
described in the Text S1 and Fig. S4. The shape of the curves and
how they change with the other cofactor are then compared to
Table 1 for a single cofactor and Table S1 for two cofactors to
determine the mechanism and order of action. Some entries in the
table require knowledge of the endogenous concentration in the
cell because the value at zero total concentration is required. This
can be obtained from Western blots.
Many of the entries in Table S1 require an estimate of the
intersection point of a set of linear regression fits to the graphs. We
used the following method to make this estimate. Consider a
family of lines y~aizbix obtained from the linear regression fits
for each graph labeled by i. The intersection point occurs if there
exists a point (x,y) that simultaneously satisfies this system of
equations. In general, because of noise and measurement error,
the lines will not intersect exactly. Solving the system simulta-
neously for the intersection point is not viable because the system
will generally be singular. However, rearranging the linear system
yields ai~y{xbi and a linear regression on the graph of a vs b,
will give the least squares maximum likelihood estimate for the
intersection points x and y. The a-intercept of the linear regression
fit corresponds to the y value, and the negative slope corresponds
to the x value, of the intersection point. The errors in the a vs b
linear regression give an indication of the likelihood that the lines
do in fact intersect.
Supporting Information
Figure S1 Linearization of transfected plasmid concen-
trations. (A) Plot of normalized OD of Western blots (above
endogenous TIF2) for different amounts of transfected TIF2
plasmid (but same amount of cell lysate protein) vs. OD of
maximum amount of transfected TIF2 (20 ng). (B) Plot of
normalized ODs of transfected TIF2 (above endogenous TIF2)
vs. ‘‘linearized plasmid’’. Amounts (ng) of linearized TIF2 plasmid
were calculated as described in the Supplementary Material and
then plotted against the normalized OD values of Fig. S1A. Error
bars=S.D. (n=2, each in duplicate).
(EPS)
Figure S2 Plots of 1/EC50 vs. cofactor for experiment of
Fig. 4. (A) 1/EC50 vs. sSMRT plasmid (corrected for non-linear
expression) with different amounts of competing NCoR plasmid.
(B) 1/EC50 vs. NCoR plasmid (corrected for non-linear expres-
sion) with different amounts of competing sSMRT plasmid.
(EPS)
Figure S3 Plots of EC50 and Amax vs. cofactor for
experiment of Fig. 5 with endogenous IGFBP1 gene. (A)
1/EC50 vs. sSMRT plasmid (corrected for non-linear expression)
with different amounts of competing TIF2 plasmid. (B) Amax/EC50
vs. TIF2 plasmid (corrected for non-linear expression) with
different amounts of competing sSMRT plasmid.
(EPS)
Figure S4 Cartoon depicting process of restricting
mechanistic scenarios of the six graphs used in analyz-
ing the competition assays. Each circle represents one type of
graph (labeled on perimeter) and is composed of different
mechanistic scenarios (e.g., Scenario A for 1/EC50 vs. F1) for
that graph (see Table 1). The area of overlap for all graphs
(depicted by the filled space in the cartoon) represents the
common, uniquely identified mechanism for that specific compe-
tition assay. This 4- to 6-fold requirement of ‘‘overlap’’ is a
stringent test for determining the mechanistic explanation of any
given competition assay.
(EPS)
Table S1 Algorithms for two factor plots for factors F1 and F2.
(DOCX)
Text S1 Derivation of the graphical method for analyzing the
competitive action of factors and Correction for non-linear protein
expression from transfected plasmids.
(DOCX)
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